Daniel Canter
Overview
Explore the profile of Daniel Canter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
751
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
de Bono J, He M, Shi Z, Nowicka M, Bracarda S, Sternberg C, et al.
Eur Urol
. 2025 Jan;
PMID: 39884884
Background And Objective: In the phase 3 IPATential150 trial, ipatasertib addition to abiraterone significantly reduced the risk of disease progression in men with metastatic castration-resistant prostate cancer (mCRPC) with PTEN...
2.
Worobey L, Canter D, Fyffe D, Slocum C, Bryce T, Swank C, et al.
Arch Phys Med Rehabil
. 2024 Oct;
106(3):379-386.
PMID: 39427781
Objective: To examine the length of time to complete wheelchair repairs and the relationship between negative outcomes and the factors that prevented or determined who performed the repairs. Design: Survey,...
3.
Narayan V, Boorjian S, Alemozaffar M, Konety B, Shore N, Gomella L, et al.
J Urol
. 2024 May;
212(1):74-86.
PMID: 38704840
Purpose: Nadofaragene firadenovec-vncg is a nonreplicating adenoviral vector-based gene therapy for bacillus Calmette-Guérin (BCG)-unresponsive carcinoma in situ (CIS) with/without high-grade Ta/T1. We report outcomes following 5 years of planned follow-up....
4.
Mitra A, Narayan V, Mokkapati S, Miest T, Boorjian S, Alemozaffar M, et al.
Eur Urol
. 2021 Dec;
81(3):223-228.
PMID: 34933753
A recent phase 3 trial of intravesical nadofaragene firadenovec reported a promising complete response rate for patients with bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer. This study examined the ability of antiadenovirus...
5.
Boorjian S, Alemozaffar M, Konety B, Shore N, Gomella L, Kamat A, et al.
Lancet Oncol
. 2020 Nov;
22(1):107-117.
PMID: 33253641
Background: BCG is the most effective therapy for high-risk non-muscle-invasive bladder cancer. Nadofaragene firadenovec (also known as rAd-IFNa/Syn3) is a replication-deficient recombinant adenovirus that delivers human interferon alfa-2b cDNA into...
6.
Fuletra J, Schilling A, Canter D, Hollenbeak C, Raman J
Int Urol Nephrol
. 2019 Oct;
52(2):197-204.
PMID: 31595382
Purpose: Adrenalectomy is an operation performed by both urologists and general surgeons; however, the majority are performed by general surgeons. We investigated whether there was a difference in outcomes based...
7.
Moret R, Hellmers L, Zhang X, Gills J, Hite N, Klinger A, et al.
J Vis Exp
. 2019 May;
(147).
PMID: 31132059
Cancer patients have poor prognoses when lymph node (LN) involvement is present in both high-grade urothelial cell carcinoma (HG-UCC) of the bladder and colorectal cancer (CRC). More than 50% of...
8.
Lotan Y, Inman B, Davis L, Kassouf W, Messing E, Daneshmand S, et al.
J Urol
. 2019 May;
202(5):920-926.
PMID: 31120373
Purpose: Single center studies have shown that positive UroVysion® fluorescence in situ hybridization results were associated with recurrence of nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guérin. Our goal...
9.
Johnstone P, Canter D, Spiess P
Eur Urol Focus
. 2019 Apr;
7(1):226.
PMID: 31000494
No abstract available.
10.
May D, Khaled D, Matrana M, Bardot S, Lata-Arias K, Canter D
Urology
. 2018 Nov;
124:154-159.
PMID: 30448368
Objective: To investigate whether patients requiring dialysis are a higher risk surgical population and would experience more perioperative adverse events even when undergoing a perceived less invasive operation as a...